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Abstract 
Background 
Aging is characterized by chronic inflammation plus muscle mass and strength loss, termed 
sarcopenia. Human Leukocyte Antigen (HLA) types are drivers of autoimmune disease, 
although with limited penetrance. We tested whether autoimmune diagnoses are associated 
with sarcopenia, and whether HLA types and related genetic variants associate with 
sarcopenia in autoimmune disease free older people.  
Methods 
Data from 181,301 UK Biobank European descent volunteers aged 60 - 70 with measured 
hand-grip strength and impedance. Logistic regression analysis estimated HLA types 
sarcopenia associations, adjusted for confounders and multiple testing.  
Results 
Having any autoimmune diagnosis was associated with sarcopenia (Odds Ratio 1.83, 95% 
Confidence Intervals 1.74-1.92, p=4.0*10
-125
). After excluding autoimmune diagnoses, six of 
100 HLA types (allele frequency >1%) were associated with sarcopenia (low grip strength 
and muscle mass). Having two HLA-DQA1*03:01 alleles increased odds of sarcopenia by 
19.3% (OR 1.19, CI 1.09-1.29, p=2.84*10
-5
), compared to no alleles. Having ≥6 of the 12 
HLA alleles increased sarcopenia odds by 23% (OR 1.23 CI 1.12-1.35, p=7.28*10
-6
).  
Of 658 HLA region non-coding genetic variants previously implicated in disease, 4 were 
associated with sarcopenia, including rs41268896 and rs29268645 (ORs 1.08, CI 1.05-1.11, 
p=1.06*10
-8
 and 1.07, CI 1.04-1.09 p=1.5*10
-6
, respectively). Some HLAs associations with 
sarcopenia were greater in female participants. 
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Conclusion 
Autoimmune diagnoses are strongly associated with sarcopenia in 60 to 70 year olds. 
Variation in specific HLA types and non-coding SNPs are also associated with sarcopenia in 
older carriers free of diagnosed autoimmune diseases. Patients with sarcopenia might benefit 
from targeted treatment of autoimmune processes. 
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Introduction 
Immuno-senescence and ‘Inflammaging’ are characterized by a low grade chronic pro-
inflammatory state associated with ageing, which results from an imbalance between the 
inflammatory and anti-inflammatory networks (1)(2). The Human Leukocyte Antigens 
(HLA) have a major role in mediating the chronic inflammatory pathway in autoimmune 
disease via antigen presentation to the CD4+/8+ T cells (3). The HLA complex has long been 
associated with autoimmune disorders and infectious disease (4). Examples of associations 
between certain HLA types and autoimmune disease include HLA-B*27 and 
spondyloarthritis (SpA), HLA-B*51 and Behcet’s disease (5), and HLA-DRB1*15:01 and 
multiple sclerosis (6)(7). Many autoimmune diseases directly impact on muscle strength and 
physical functioning, however autoimmune diseases are generally not monogenic or fully 
penetrant, but rather are complex polygenic diseases influenced by environmental factors 
(despite having over 110 linked genes, excluding HLA types, the heritability of multiple 
sclerosis is approximately 28% (8)). We hypothesise therefore that both those with diagnosed 
auto-immune conditions and carriers of certain HLA types without diagnosed autoimmune 
diseases may have increased risk of age related conditions. 
Sarcopenia, loss of muscle mass and strength during ageing, is associated with reduced 
physical functioning and is associated with increased risks of morbidity (including falls and 
fractures) and mortality (9)(10). The European Working Group on Sarcopenia in Older 
People (EWGSOP) defines age-related Sarcopenia to include both low muscle mass and low 
muscle function (9). The Baltimore Longitudinal Study of Aging (BLSA) found evidence that 
this can occur as early as age 40 in both men and women (11), with progressive decline over 
time. However studies of age-related sarcopenia commonly use an age range of 60 or older, 
to exclude  causes of muscle weakness earlier in life (12). Previous studies have presented 
evidence for the role of inflammation in sarcopenia (13)(14), and it is becoming apparent that 
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contributors to disease vary in penetrance from Mendelian disorders to complex diseases 
(15). We hypothesise that certain HLA types may increase risks for sarcopenia, possibly via 
undiagnosed or subclinical autoimmune processes. While muscle loss is a classical feature of 
multiple sclerosis and some other autoimmune conditions, little is known of whether carrying 
certain HLA types predisposes to autoimmunity which in turn accelerates muscle loss in later 
life.  
We aimed to test associations between diagnosed autoimmune conditions and sarcopenia in 
the exceptionally large UK Biobank study. We also aimed to test associations between 
common HLA types and sarcopenia in individuals independently of any diagnosed 
autoimmune condition, using three definitions of sarcopenia (European Working Group on 
Sarcopenia definition published in 2010; Low grip strength and lean muscle mass combined, 
grip strength only and lean muscle mass only). We hypothesise that the presence of certain 
HLA types are more common in sarcopenic individuals in later life, even in the absence of 
diagnosed autoimmune disease.  
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Methods  
We used data from 451,447 UK Biobank participants of European descent, confirmed by 
principal components analyses of genome-wide genetic information from a selection of 
participants who self-identified as ‘white European’(16). The UK Biobank is a volunteer 
study where participants visited one of 22 assessment centres across the UK. A range of 
physiological and questionnaire data was collected, including genetic data from blood draws 
(17). Genotyping data was generated on the initial ~50,000 participants using the Affymetrix 
UK BiLEVE Axiom array and the ~450,000 participants of the remaining cohort were 
genotyped using the Affymetrix UK Biobank Axiom array - the two arrays sharing over 95% 
similarity (http://www.ukbiobank.ac.uk).  
 
Phenotype definitions 
Sarcopenia was classified using the EWGSOP definition (9), based on having both low hand 
grip strength and skeletal muscle mass index (SMI). For grip strength the highest value from 
hand grip strength, left and hand grip strength, right was taken as the selected metric. Low 
grip strength was defined as under 30kg in Males and under 20kg in Females, as measured by 
Jamar J00105 hydraulic hand dynamometer.  
Skeletal muscle mass (SMM) was calculated using the following equation from Janssen et al 
(18); 
      g    Ht            gender         age                 
Where Ht is standing height in centimetres measured at the initial assessment; R is 
Bioelectrical Impedance Analysis (BIA) resistance in ohms for the whole body taken by 
Tanita BC418MA body composition analyser at the initial assessment visit; for sex, men = 1 
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and women = 0; and age is in years. A Skeletal muscle mass index (SMI) was then calculated 
from the SMM. 
        Ht in  eters  
Low SMI was defined by Janssen et al. as under 8.87 in Males and under 6.42 in Females. 
Analysis was restricted to the age range of 60-70. We excluded a small number participants 
with max grip strength or lean mass (from BIA) greater than 4 standard deviations from the 
mean (SMI > 46.61; max grip > 73.91). 
Three definitions of sarcopenia were developed based on the EWGSOP classification using 
both grip and lean muscle mass (grip strength 30kg for males and 20kg for females, Low SMI 
8.87 for males and 6.42 for females), low grip strength only (grip strength 20kg for females 
and 30 kg for males) and low muscle mass only (Low SMI 6.42 for females and 8.87 for 
males). While DXA (Dual-energy X-ray absorptiometry) is the preferred alternative to CT 
and MRI for estimating muscle mass, EWGSOP deemed that BIA may be considered as a 
portable alternative to DXA. 
The FNIH definition of sarcopenia (19) based on low grip strength and appendicular lean 
mass could not be analysed with the cohort due to less than 0.2% / 0.1% of the female / male 
participants meeting the criteria. 
 
Auto-immune disease exclusions 
Some autoimmune diseases are known to influence muscle loss. We aimed to determine 
whether HLA-types were associated with sarcopenia in the absence of diagnosed 
autoimmune disease, and we therefore excluded participants with a diagnosis at the baseline 
assessment (self-reported or hospital diagnosed).  
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A list of 135 (including sub-groups) ICD-10 codes for autoimmune diseases were generated 
from previous review articles (20) and the codes used to exclude participants from the initial 
analysis (Supplementary Table 1). In addition, UK Biobank self-reported data was also used 
based on the autoimmune conditions in the ICD-10 list. Following the initial analysis an 
additional 55 autoimmune diseases associated with the HLA types were added to the 
exclusion criteria and formed the basis of the secondary analysis (Supplementary Table 2).  
Logistic regression was performed on a selected subset of more common autoimmune 
conditions such as Rheumatoid Arthritis, Multiple Sclerosis, Coeliac disease, Type 1 
Diabetes, Psoriasis and Ulcerative colitis. In order to include as many participants as possible 
with each condition all ICD-10 codes belonging to the superclass of each condition were 
included (for example, all ICD-10 codes for M06* are included for Rheumatoid Arthritis), as 
well as any self-reported in the UK Biobank (Supplementary Table 10 for details). 
 
HLA imputation 
Imputation of HLA types was performed centrally by the UK Biobank team. In brief, 
HLA*IMP:02 (21) was used to impute the four-digit HLA types from genotype information, 
with a number of modifications: localization feature turned off; graph sampling error (mS) 
and graph building error (mB) probabilities were both set to 0.001; and the number of 
sampled haplotype pairs was set to 5 (22). Individuals are therefore coded as 0, 1 or 2 
depending on the number of HLA alleles carried for each gene. The methods allow for 
imprecise coding (e.g. 1.92) to indicate the confidence in HLA type imputation. Some HLA 
type codes indicate unknown or other HLA types (e.g. *99:01), and these were not included 
in analyses. HLA-types below 1% frequency were excluded from analyses to account for 
lower quality imputation for rarer alleles. 
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Statistical Analysis 
Logistic regression analyses were performed for each HLA type against sarcopenia, adjusted 
for age, sex, genotype array, and the first five principal components for ancestry.  Cohorts 
were restricted to the age range 60 to 70 and of European descent. Participants with known 
autoimmune disease were excluded as previously described, based on Hospital Episode 
Statistics data (ICD-10 codes) and self-reported fields. 
HLA types were modelled first assuming an additive effect, and secondly comparing 
participants with 2 alleles to those with 0. Participants with imprecise HLA imputations were 
recoded for the second, categorical analysis (i.e. estimated allele dose between 0 and 0.25 set 
to 0, values between 0.75 and 1.25 set to 1, and finally between 1.75 and 2 to 2; other doses 
were set to missing due to imprecise imputation). Correction for multiple testing was applied 
using the Benjamini-Hochberg method, for the additive and recessive models separately as 
these were independent hypotheses. Statistical analyses were performed in STATA (v14.1) 
and R (v3.3.2). Charts and figures were generated with package metafor (v2.0). 
After analysing each HLA type for its association with sarcopenia we performed a literature 
search to identify any autoimmune diseases implicated by the significant HLA types not 
already included in the autoimmune exclusion criteria.  HLA type associations with 
sarcopenia were reanalysed after participants with a diagnosis of these further autoimmune 
conditions had been excluded (Supplementary Table 2); these are the final results presented. 
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Sex specific cohort analysis 
HLA types associated with the three definitions of sarcopenia was analysed with sex-specific 
cohorts, after the removal of participants with autoimmune conditions. We tested for a 
statistical interaction between sex and HLA type on sarcopenia, in the models described 
previously. 
 
Sensitivity analyses 
Sensitivity analysis was performed on the HLA types associated with sarcopenia across the 
three phenotypes, for smoking status (UKB data-field: 20116) and a combination of height 
and weight. 
 
Non-coding SNPs associated with a phenotype in previous Genome-Wide Association 
Studies. 
The HLA types assessed so far were based on the protein-coding sequence of the HLA 
protein expressed. We also investigated non-coding SNPs within the HLA region that have 
previously been associated with traits in the GWAS catalogue; SNPs in the HLA region (4) 
between GRCh.v38: Chr6:29545629 (start of GABBR1 transcript ENST00000355973.7, 
minus 10Kb) and GRCh.v38: Chr6:33419924 (end of KIFC1 transcript 
ENST00000428849.6, plus 10 Kb) were downloaded from the NHGRI-EBI GWAS 
Catalogue(23). SNPs labelled with one or more of the following contexts were excluded 
stop_gained, synonymous_variant, missense_variant, non_coding_transcript_exon_variant, 
frameshift_variant or inframe_deletion, in order to prioritise variants with a possible 
regulatory role over variants involved in changes to protein coding. The 658 SNPs associated 
D
ow
nloaded from
 https://academ
ic.oup.com
/biom
edgerontology/advance-article-abstract/doi/10.1093/gerona/glz042/5321878 by U
niversity of Exeter user on 27 February 2019
Ac
ce
pte
d M
an
us
cri
pt
 
 
with a reported trait (p-value < 5*10
-8
, Supplementary Table 3) and had available genotype 
data in the UK Biobank were included in the analysis (frequency ≥1% in order to account for 
lower quality imputation for rarer SNPs). These were tested for their association with sarcopenia 
using the methods described above for HLA type analysis. We used the Bonferroni adjusted 
cut-off for 658 tests of p-value < 7.6x10
-5
. Associations between these SNPS and sarcopenia-
associated HLA types were also calculated. The GTEx database (24) was used to identify 
genes with expression affected by the alleles of the genetic variants. A threshold of 3.66*10
-8
 
(0.05 / 4 independent lead SNPs * 341316 GTEx v7 eGenes) was used to select the most 
significant eQTLs. 
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Results 
We selected 196,099 UK Biobank participants of European descent aged 60-70 with 
complete phenotype, diagnosis, and genotype data for investigation. Of these, 14,798 
participants had at least one diagnosed autoimmune disease (including type-1 diabetes, 
multiple sclerosis, and rheumatoid arthritis, see methods for details). Participants with a 
diagnosed autoimmune disease had increased odds of meeting the EWGSOP sarcopenia 
criteria (Odds ratio 1.83, CI 1.74-1.92, p=4.0*10
-125
; Table 1). There were specific 
associations with Rheumatoid Arthritis (n=2,833): mean grip strength in this group was 22.1 
(SD 11.3) Kg compared to 31.0 (SD 10.8) Kg (p < 0.001) for all other participants in the 
European 60-70 age group. Associations were also present for multiple sclerosis, coeliac 
disease and psoriasis, but not for type 1 diabetes or ulcerative colitis.  
After excluding those with autoimmune diagnoses, the remaining 181,301 participants had a 
mean age of 64.1 years and 95,340 were female (Table 2). Of 85,961 men included in the 
analysis, 3,510 were defined as having sarcopenia (4.08%), and of 95,340 women there were 
11,540 defined as sarcopenic (12.10%).  
Of 100 HLA types with allele frequency >1%, six were associated with sarcopenia 
(EWGSOP definition) in logistic regression models adjusted for age, sex, genotyping array 
type, and population structure (genetic principal components 1-5), after accounting for 
multiple testing (FDR<5%) (Figure 1). We compared participants with two alleles of each 
HLA-type to those with zero alleles; participants homozygous for HLA-DQA1*03:01 have 
19.3% (Odds Ratio 1.19, 95% Confidence Intervals 1.10-1.30, p=2.84*10
-5
) increased 
likelihood of sarcopenia, compared to those without HLA-DQA1*03:01 (Supplementary 
Table 4.) and HLA-DRB4*01:03 homozygotes had a 15.4% increased likelihood of 
sarcopenia (Odds ratio 1.15, CI 1.08-1.23, p=2.66*10
-5
). When the six HLA-types were 
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combined, participants with at least six alleles (of a possible 12 - each person can have up to 
two alleles of each HLA type) had 23% increased likelihood of sarcopenia (n= 5,685 
participants of 181,301; OR 1.23, 95% CI 1.12-1.35, p=7.28*10
-6
).  
Seven HLA-types were associated with the sarcopenia definition based on grip strength 
alone, and six were associated with the sarcopenia muscle mass definition, with no overlap 
between the alleles associated with the two phenotypes (Figure 1 and Supplementary Table 
5). All of the top HLA type associations for the EWGSOP definition of sarcopenia were also 
present in the low grip phenotype, with the exception of HLA-C*15:02 which did not reach 
significance after correction for multiple testing in the low grip phenotype analysis. 
Conversely, the HLA types associated with low muscle mass (HLA-B*27:05 OR 1.079, 95% 
CI 1.04-1.12, p=1.64*10
-5
; HLA-C*01:02 OR 1.093, 95% CI 1.05-1.13, p=1.65*10
-6
 and 
HLA-C*02:02 OR 1.059, 95% CI 1.02-1.10, p=1.46*10
-3
) were distinct from those 
associated with the EWGSOP definition of sarcopenia. 
Sex specific analysis 
We tested for interactions between HLA types and sex on sarcopenia. Two HLA types, HLA-
DQA*03:01 (p=0.032) and HLA-DRB1*04:04 (p=0.038), were nominally associated with 
sarcopenia (EWGSOP combined definition); indicating that the effect of these HLA types is 
significantly greater in females, compared to males. The other interactions were not 
significant, although we cannot rule out lack of statistical power due to the relatively low 
numbers of men with sarcopenia (Supplementary Table 5). 
There were three additional HLA types associated with the EWGSOP combined definition of 
sarcopenia in the female only analysis (HLA-B*15:01 OR 1.089, 95% CI 1.03-1.15, 
p=3.27*10
-3
; HLA-DRB1*04:04 OR 1.107, 95% CI 1.03-1.19, p=3.65*10
-3
 and HLA-
DQB1*03:02 OR  1.07, 95% CI 1.02-1.12, p=3.2*10
-3
), which were not identified in the 
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analysis including both sexes (FDR-adjusted p>0.05). In the analysis of males only, there 
were no significant (FDR-adjusted p>0.05) associations between HLA-types and sarcopenia.  
 
Sensitivity analyses 
In sensitivity analyses we investigated the effect of adjusting for height and weight; all the 
reported risk increasing associations between HLA-types and sarcopenia remained 
significant, with nominal changes to effect sizes (Supplementary Table 6). However, the 
three protective HLA-types associated with the sarcopenia grip definition were non-
significant after adjusting for height and weight (p > 0.05) in the combined cohort. In the 
Female only cohort the protective HLA type DRB1*15:01 was the only HLA-type to lose 
significance. The Lean Muscle Mass only phenotype maintained the significance of the 
previously observed HLA-types, except in the case of HLA-C*01:02 in the Female only 
cohort which lost its significant association with sarcopenia.  
Adjustment for smoking status had no impact on the associations between HLA types and 
sarcopenia, for any of the three phenotypes analysed or across the three cohorts of all 
participants, female only and male only (Supplementary Table 6).  
 
Non-coding Single Nucleotide Polymorphisms in HLA region 
We analysed 658 non-coding SNPs (frequency ≥ 1% in order to li it the number of statistical 
tests undertaken and  to avoid misclassification from  lower quality imputation for rarer 
SNPs) within the HLA region previously implicated in human traits at genome wide 
significance (p<5*10
-8
) available in the UK Biobank genotype data. We found 219 SNPs 
nominally (p<0.05) associated with the EWGSOP definition of sarcopenia (Supplementary 
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Table 7). 10 SNPs reached the Bonferroni adjusted cut-off of 7.6x10-5. Of these, we 
identified 4 independent signals (Table 3), after removing those in linkage disequilibrium (R
2
 
>0.4, see Supplementary Table 8). This included rs41268896 and rs2293751 with p-values < 
5*10
-8
 (ORs = 1.079 and 1.069, respectively). 
We interrogated the GTEx eQTL (expression quantitative trait loci) database of SNP-
expression associations to determine the likely genes affected by these 4 genetic variants 
(Table 3, see Supplementary Table 9 for full details), using a stringent significance threshold 
of p<3.66*10
-8
. This included specific HLA genes, here listed with the tissue in which the 
strongest eQTL was found (HLA-DQA2 - Skeletal Muscle, HLA-DQB2 – Whole Blood, 
HLA-DQB1 – Whole Blood, HLA-DRB6 – Skeletal Muscle, HLA-DRB9 - Thyroid, HLA-
DRB1- Skin, Sun exposed lower leg, and HLA-DQA1 - Lung), in addition to other genes 
with plausible mechanisms of action in sarcopenia (ATF6B – Skeletal Muscle, CYP21A1P – 
Subcutaneous Adipose, BAG6 – Tibial Artery, CSNK2B – Left Heart Ventricle, LY6G5C - 
Thyroid, PSORS1C1 - Thyroid, C2 - Testis). We also searched for protein QTLs in a recent 
paper by Sun et al. (25) and found that rs41268896 is highly correlated (R
2
=0.8 in UKB) with 
rs8111, a pQTL for ATF6A. 
We also investigated the combined effect of the 4 non-coding SNPs; participants with at least 
4 effect alleles (of a possible 8), showed an increased likelihood of sarcopenia of 11% (n= 
74,820 participants of 181,301; OR 1.11, 95% CI 1.08-1.15, p=1.06*10
-9
).  
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Discussion 
To the best of our knowledge, this is the first large human population study of HLA effects 
on sarcopenia in older people. First, we have shown that autoimmune diagnoses are strongly 
associated with sarcopenia in our sample of 60 to 70 year old community volunteers, with 
particularly large effect for rheumatoid arthritis (OR 3.09, 95% CI 2.87 to 3.34), plus 
multiple sclerosis, coeliac disease and psoriasis, but not for type 1 diabetes or ulcerative 
colitis.  
After excluding participants with autoimmune diagnoses, we identified 6 HLA types 
associated with sarcopenia in 181,301 UK Biobank participants of European descent aged 60-
70. Although these have modest effect sizes (per allele odds ratios from 1.054 to 1.15) they 
are common in the study population, ranging in frequency from 3.7% to 24.8%. In 
combination, participants with more than six of the HLA-types had markedly increased 
likelihood of sarcopenia (OR 1.23, 95% CI 1.12 to 1.35). We observed markedly different 
prevalence of sarcopenia in males and females (4% vs 12%); although a recent systematic 
review found that the average sarcopenia prevalence in males and females was approximately 
10% (26), the individual studies varied considerably and it was not unusual to observe 
substantial sex differences. We performed sex-stratified analysis of HLA-types and found 
that all observed associations were only statistically significant in females, and for some this 
sex-interaction was statistically significant, suggesting that the effect of HLA-DQA1*03:01 
and HLA-DRB1*04:04 are substantially greater in females compared to males. Unfortunately 
the study lacked the power required for the male only cohort to observe Odds Ratios within 
the ranges seen in the combined sex analysis. 
We also identified 4 non-coding genetic variants in the HLA region of chromosome 6 
associated with sarcopenia. These are known to affect the expression of multiple genes, 
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including HLA genes, in multiple tissues including skeletal muscle. Although more evidence 
is required for a clear causal link, this suggests that regulation in expression of HLA genes 
may also be an important driver of sarcopenia, not just the protein sequence (HLA-types). 
When taken in combination participants with more than four of the effect alleles had an 11% 
increased likelihood of sarcopenia. 
The EWGSOP 2010 definition of sarcopenia (27), which combines low grip strength and low 
muscle mass, shares many of the associated HLA alleles with those seen in low grip strength 
definition alone. In contrast, there is little overlap with the low muscle mass definition. Often, 
grip strength alone is used to identify “frail” participants in population studies (28) as it is the 
maintenance of function that appears most important. 
HLA-types associated with sarcopenia are also associated with conditions linked to joint pain 
and loss of function, such as rheumatoid arthritis (DRB1*04:01), ankylosing spondylitis 
(C*15:02), Behcet’s  disease (B*51:01, joint swelling and pain prevalence in 45-60% of 
cases (29)), and neuropathic pain (DQB1*03:02, although a meta-analysis (30) only showed 
association to the two-digit allele DQB1*03). Other HLA alleles associated with sarcopenia 
include DQA1*03:01, which has been linked to pemphigus vulgaris, a painful autoimmune 
condition which can affect the skin, mouth and groin with blisters. In addition a previous 
study (31) of HLA types and the self-reported fields for Rheumatoid Arthritis in the UK 
Biobank has shown an association between DQA1*03:01and the disease (OR 1.77, CI 1.70-
1.85, p=1.5*10
-131
, moderate linkage disequilibrium with HLA-DRB1*04:01 r
2
 = 0.5 ). 
 DQB1*03:01 has only been shown to have an association previously as a protective allele 
against primary biliary cholangitis, although this study provides evidence of a novel 
association with sarcopenia. In this analysis we excluded participants with a self-reported or 
hospital diagnosis of autoimmune conditions, including those mentioned here, suggesting that 
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the associations observed here are not due to diagnosed conditions. More work is needed on 
whether these associations are due to a general pro-inflammatory effect or represent sub-
clinical manifestations of specific autoimmune processes. More work is also needed on 
whether some patients with sarcopenia have evidence of autoimmune processes and might 
benefit from targeted treatment. 
Some HLA types were protective for sarcopenia: increasing copies of DQB1*06:02, 
DRB5*01:01 and DRB1*15:01 were all associated with reduced likelihood of sarcopenia, 
and have previously been implicated in a number of studies in the development of multiple 
sclerosis (6), although mainly as part of an extended haplotype including all three types. 
When we compared participants carrying two alleles of each HLA to those with zero we 
found far greater effect sizes; for example the likelihood of being sarcopenic for 
DQA1*03:01 rises from 6% to 19.3%, suggesting recessive effects. DRB4*01:03 has been 
reported as appearing with  increased frequency in a limited study of Brazilian patients with 
polyarteritis nodosa (32). Association of DRB4*01:03 with rheumatoid arthritis has mixed 
evidence in the literature with recent studies showing no association (33), while slightly older 
and smaller studies in a different population showing a link (34). HLA-DQA1*03:01 has 
been previously shown to increase the risk of type 1 diabetes (35), when present as part of the 
DR4 haplotype or in conjunction with DQB*02:01 (36). 
The analysis of low grip strength alone reinforced the associations seen in the EWGSOP 
sarcopenia definition analysis, with only a single additional association for DQA1*01:02. 
This type was protective against low grip strength and reported as associated with a multiple 
sclerosis-like condition in transgenic mice (37). HLA alleles were only associated with low 
muscle mass using the additive model, C*01:02 and B*27:05, both of which have previously 
been linked to forms of arthritis – psoriatic arthritis (38) and spondyloarthritis (39). Neither 
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type appeared in the associations for the combined EWGSOP phenotype of sarcopenia, 
suggesting potential independent effects. 
In our analysis of non-coding genetic variation in the HLA-region we identified 4 genetic 
variants associated with sarcopenia. These SNPs also affect expression of genes other than 
HLAs, including ATF6B, which encodes a transcription factor in the unfolded protein 
response (UPR) pathway during endoplasmic reticulum (ER) stress and there has been 
speculation that ER stress may impair autophagy and myogenesis activity resulting in 
sarcopenia (40) (41). rs41268896 is strongly correlated with the rs8111 (R2=0.8), known to affect 
protein levels of ATF6A (25), which binds as a heterodimer with ATF6B. The rs41268896 A allele 
increases ATF6B expression, whilst the rs8111 T allele (co-inherited) decreases ATF6A protein 
levels, suggesting a complex relationship; more work is required to understand this. The BAG6 
protein product is also involved in elimination of misfolded proteins, including class-I HLA 
products (42) (43).  CYP21A2 has a role in producing cortisol and aldosterone as part of the 
hypothalamic-pituitary-adrenal (HPA) axis, disruption to the HPA has been linked to decline 
in physical function and aging (44)(45). 
The strengths of this study include the large number of older participants with consistent 
sarcopenia measurements and medical records data available for analysis. However, it is a 
volunteer study and will therefore be healthier than the general population: effects of HLA 
types on sarcopenia may therefore be underestimated in this study. Future studies should 
investigate other definitions of sarcopenia, such as those from the FNIH (46) and the revised 
2018 version of the EWGSOP definitions (47) which result in differing prevalence (19) due 
to different cut-points and muscle mass measurements, in older populations. Additionally, 
autoimmune diagnoses may be under-reported as diagnoses are either self-reported or from 
hospital in-patient records only; further studies will be required. Future work should clarify 
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the associations between HLA-types, circulating inflammatory cytokines, and frailty, ideally 
in a longitudinal study.   
Given the biologically plausible and strong association between autoimmune diseases and 
sarcopenia, our finding in the autoimmune diagnosis free group are also plausible. Although 
all reported associations passed multiple statistical testing correction our results, especially in 
men, do require independent replication, as the effects observed may vary between cohorts, 
although sample size requirements for replication will be challenging. 
Functional follow-up work on the HLA types that we have found associated with sarcopenia 
could give an indication of the underlying mechanisms at work. The mechanisms of effect of 
the HLA region and specific HLA types in seropositive Rheumatoid Arthritis (48) and other 
autoimmune diagnoses have been identified, and it needs to be established whether similar 
mechanisms explain associations with sarcopenia.  
Conclusions 
Autoimmune diagnoses are strongly associated with sarcopenia in 60 to 70 year olds. In older 
participants without diagnosed autoimmune diseases we identified 6 HLA-types associated 
with EWGSOP sarcopenia definition. An additional four unique HLA types were associated 
with the low grip strength only and six types associated with the low Skeletal Muscle Index 
(SMI) definition only. Additional analysis of non-coding variants showed that SNPs involved 
the regulation of HLA, endoplasmic reticulum stress response and immune function genes are 
also associated with sarcopenia. Further studies into the long-term effects of HLA variation 
are required. More work is needed on whether some patients with sarcopenia have 
autoimmune processes and might benefit from targeted treatment. 
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Figure 1: Forest plot of HLA types associated with Sarcopenia phenotypes. 
 
Note: Logistic regression analysis of 100 HLA-types associated with sarcopenia (Benjamini-
Hochberg correction for multiple testing applied). OR=Odds Ratio per allele of HLA-type, 
CI=Confidence Interval, EWGSOP=Combined sarcopenia definition: low grip and muscle mass. HLA 
types passing the FDR cut-off of 0.05 for each phenotype are marked with asterisks (*) 
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Table 1: Selected Autoimmune conditions and their association with the EWGSOP definition of 
sarcopenia (Low grip strength and Lean muscle mass) in the overall sample of 196,099 UK Biobank 
participants. 
 
 
Note: Supplementary Table 10 has full details of additional sarcopenia definitions. 
  
Description Affected n Odds Ratio (95%CIs) P-value 
 Rheumatoid Arthritis 4,103 3.09 (2.87-3.34) 6.00*10
-191
 
Multiple Sclerosis 588 2.14 (1.73-2.64) 1.60*10
-12
 
Coeliac disease 1,001 1.82 (1.54-2.17) 6.00*10
-12
 
Psoriasis 2,951 1.31 (1.16-1.48) 1.20*10
-05
 
Type 1 Diabetes 1,565 1.14 (0.95-1.36) 1.70*10
-01
 
Ulcerative colitis 2,077 1.13 (0.97-1.32) 1.00*10
-01
 
Any autoimmune 14,798 1.83 (1.74-1.92) 4.0*10
-125
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Table 2: UK Biobank Participants Characteristics, excluding those with autoimmune conditions   
 
    n min-max mean (SD) 
   Age of study participant (years) 181,301 60-70 64.11 (2.85) 
   
BMI (Kg/m2) 181,301 
12.81-
68.41 
27.52 (4.46) 
   
 
  
      
Grip strength (Kg) 181,301 0-73 
31.09 
(10.71) 
   Skeletal muscle mass (Kg) 181,301 8.57-46.13 21.96 (6.00) 
   
  
  
  
   
 
  
  
Sarcopenia EWGSOP 
 
  
  
No Yes 
    n % n % n % 
Gender 
  
        
 
Female 95,340 52.59 83,800 87.90 11,540 12.10 
 
Male 85,961 47.41 82,451 95.92 3,510 4.08 
 
Combined 181,301 100.00 166,251 91.70 15,050 8.30 
 
  
  
  
   Highest education level attained 
  
  
   
 
None 48,224 26.60 43,150 89.48 5,074 10.52 
 
Secondary 28,870 15.92 26,096 90.39 2,774 9.61 
 
College-level 26,810 14.79 25,006 93.27 1,804 6.73 
 
Professional/University 75,075 41.41 69,882 93.08 5,193 6.92 
 
No data 2,322 1.28 2,117 91.17 205 8.83 
 
  
  
  
   Smoking status 
  
  
   
 
Never 90,242 49.77 82,112 90.99 8,130 9.01 
 
Previous 75,618 41.71 70,031 92.61 5,587 7.39 
 
Current 14,602 8.05 13,356 91.47 1,246 8.53 
 
No data 839 0.46 752 89.63 87 10.37 
 
Note: UK Biobank participants aged 60-70 of European descent with complete grip strength, skeletal 
mass, genotype (HLA), and autoimmune diagnosis data. Participants with a diagnosis of autoimmune 
diseases were excluded from analyses.
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Table 3: Non-coding SNPs within the HLA region associated with EWG OP definition of sarcopenia (p ≤ 1.0 x 10-5) with gene expression information  
RS id A1/A0 CHR:POS Trait OR 95% CI  p-value Expressed gene(s) P < 3.66*10
-8
 Tissue type* 
rs41268896 ¥ A/G 6:32070069 Atopic 
dermatitis 
1.08 1.05-1.11 1.06*10
-8
 ATF6B, CYP21A1P, BAG6, HLA-
DQA2 
MS, AS, AT, 
WB 
rs2844479 C/A 6:31572956 Height 1.07 1.04-1.09 6.11*10
-7
 BAG6, ATF6B, CSNK2B, LY6G5C AT, MS, HLV, 
TH 
rs9268645 † G/C 6:32408527 T1 diabetes 1.06 1.04-1.09 1.50*10
-6
 HLA-DQA2, HLA-DQB2, HLA-
DQB1, HLA-DRB6, HLA-DRB9, 
HLA-DRB1, HLA-DQA1 
MS, WB, WB, 
MS, TH, SE, 
LN 
rs2072633 G/A 6:31919578 Coronary 
artery disease 
1.06 1.03-1.08 3.58*10
-6
 CYP21A1P, ATF6B, HLA-DQA2, 
PSORS1C1, C2 
AS, MS, WB, 
TH, TE 
 
Note: A1=Effect allele, A0=Reference allele, POS=build 37 base pair, OR=Odds Ratio, CI=95% Confidence Intervals. Trait = the top identified trait from the 
GWAS catalogue. * Tissue type: Adipose Subcutaneous=AS; Artery Tibial=AT; Colon Sigmoid=CS; Esophagus Muscularis=EM; Muscle_Skeletal=MS; 
Nerve Tibial=NT; Skin Sun exposed lower leg=SE; Thyroid=TH; Whole Blood=WB; Heart Left Ventricle=HLV; Testis=TE; Lung=LN. † correlated with 
DQA1*03:01 (R
2
=0.42). ¥ in LD with protein QTL for AFT6A (R
2
=0.8 with rs8111 in UKB) (25). GTEx genes for each variant shown, which reached a 
threshold of 3.66*10
-8
 for the Nominal P-value in GTEx (with the most significant tissue type for that eQTL shown also) – see Supplementary Table 9 for all 
eQTL associations. Expressed genes in bold are downregulated in GTEx by the Effect Allele, all others are upregulated.
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